Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design.
Saved in:
| Title: | Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design. |
|---|---|
| Authors: | Groarke JD; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA., Crawford J; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA., Collins SM; Global Biometrics and Data Management, Pfizer R&D UK Ltd, Sandwich, Kent, UK., Lubaczewski SL; Early Clinical Development and Biomedicine Artificial Intelligence, Pfizer Inc, Collegeville, PA, USA., Breen DM; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA., Harrington MA; Global Access and Value, Pfizer Inc, Cambridge, MA, USA., Jacobs I; Global Product Development, Pfizer Inc, New York, NY, USA., Qiu R; Clinical Pharmacology, Pfizer Inc, Cambridge, MA, USA., Revkin J; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA., Rossulek MI; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA., Saxena AR; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA. |
| Source: | Journal of cachexia, sarcopenia and muscle [J Cachexia Sarcopenia Muscle] 2024 Jun; Vol. 15 (3), pp. 1054-1061. Date of Electronic Publication: 2024 Mar 18. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders Country of Publication: Germany NLM ID: 101552883 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2190-6009 (Electronic) Linking ISSN: 21905991 NLM ISO Abbreviation: J Cachexia Sarcopenia Muscle Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2190-6009 |
|---|---|
| DOI: | 10.1002/jcsm.13435 |
